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The prevalence of non-fatal overdose among people who inject drugs: a multi-stage 
systematic review and meta-analysis 
Background: People who inject drugs (PWID) are at an elevated risk of fatal overdose in the first year after 
experiencing a non-fatal event. Such non-fatal events may also result in overdose-related sequelae, ranging from 
physical injury to paralysis. Given variation in drug markets and treatment availability across countries and regions, 
we may see similar variations in non-fatal overdose prevalence. Monitoring non-fatal overdose prevalence among 
PWID is essential for informing treatment intervention efforts, and thus our review aims to estimate the global, 
regional, and national prevalence of non-fatal overdose, and determine characteristics associated with experiencing 
such an event. 
Methods: We conducted a systematic review and meta-analyses to estimate country, regional, and global estimates 
of recent and lifetime non-fatal overdose prevalence among PWID. Using meta-regression analyses we also 
determined associations between sample characteristics and non-fatal overdose prevalence. 
Results: An estimated 3.2 (1.8-5.2) million PWID have experienced at least one overdose in the previous year. 
Among PWID, 20.5% (15.0-26.1%) and 41.5% (34.6-48.4%) had experienced a non-fatal event in the previous 12 
months and lifetime respectively. Frequent injecting was strongly associated with PWID reporting recent and 
lifetime non-fatal overdose. Estimates of recent non-fatal overdose were particularly high in Asia and North 
America.  
Conclusion: Around one in five PWID are at an elevated risk of fatally overdosing every year, however there is 
substantial geographical variation. In countries with higher rates of non-fatal overdose there is need to introduce or 
mainstream overdose prevention strategies such as opioid agonist treatment and naloxone administration training 
programs. 
Funding: The Australian National Drug and Alcohol Research Centre, Australian National Health and Medical 
Research Council, University of New South Wales 






People who inject drugs (PWID) are vulnerable to experiencing a wide range of harms that can cause extensive 
morbidity and mortality. It is estimated that there are between 10 and 24 million PWID globally (Degenhardt et al., 
2017), and the leading cause of death among this population is drug overdose (Mathers et al., 2013). Due to the 
rapid onset of intoxication, PWID are more vulnerable to overdose than people who use drugs through other routes 
of administration (Degenhardt et al., 2011; Hickman et al., 2003; Kaye & Darke, 2004). Thus, monitoring the 
prevalence of non-fatal overdose among PWID should be key in informing the introduction and appropriate scale-up 
of interventions that aim to reduce mortality and morbidity (Britton, Wines, & Conner, 2010; Caudarella et al., 
2016; Evans et al., 2012; Martins, Sampson, Cerda, & Galea, 2015). 
Cocaine, opioids and non-opioid analgesics are most commonly associated with overdose, compared to other 
substances (Martins et al., 2015). Opioid overdose is characterized by depressed respiration, loss of consciousness 
and cyanosis (White & Irvine, 1999). Stimulant toxicity, however, may result in arrhythmias, severe tachycardia, 
increased body temperature, tremors, severe anxiety, agitation, or panic, chest pain, nausea, vomiting, palpitations, 
seizure or stroke (Karch, 1996; Kaye & Darke, 2003; Vasica & Tennant, 2002). Due to the relatively short half-life 
of cocaine and other stimulants, the effects of a stimulant overdose are often brief and may not be interpreted as 
such. Further, polydrug use is typical among PWID and toxicity from a number of drugs is common in overdose 
presentations (Di Rico, Nambiar, Stoove, & Dietze, 2018). Mortality due to overdose, or poisonings, is often 
captured in routinely collected data in most developed countries. We therefore have a broad and accurate 
understanding of the rates of overdose fatality in the general population, but limited understanding of non -fatal 
events. 
Non-fatal overdose is a major risk factor for both subsequent fatal overdose and morbidity (Boyes, 1994). Opioid 
overdose is associated with sequelae such as physical injury, peripheral neuropathy, paralysis, vomiting and chest 
infections (Warner-Smith, Darke, & Day, 2002; Warner-Smith, Darke, Lynskey, & Hall, 2001). A sizable 
proportion of PWID (up to 80%) who overdose on opioids are impacted by one or more of these sequelae (Warner-
Smith et al., 2002). It is difficult to assess whether cocaine overdose results in morbidity distinguishable from 




however both are associated with cardiovascular complications, hyperthermia, and vasospasms  (Connors & 
Hoffman, 2013; Lange & Hillis, 2001).  
Ambulance data are often used to understand rates of overdose, but we know that a significant number of those who 
experience a non-fatal event do not receive medical help (D. Kerr, Dietze, Kelly, & Jolley, 2009). This is where self-
report data from PWID are critical in terms of understanding experience of overdose, both personal and witnessed 
events. A recent systematic review has attempted to synthesize the literature on this topic, however was limited to 
data from peer-reviewed studies with PWID sampled in Western countries between 1993 and 2006 (Martins et al., 
2015).  
It is also important to understand the proportion of PWID who are witnessing others’ overdoses and have the 
opportunity to intervene (e.g. through the administration of naloxone). There is good evidence that supports 
naloxone administration training programs and take-home kits for peers as effective overdose prevention strategies 
(Barocas, Baker, Hull, Stokes, & Westergaard, 2015; Chronister et al., 2018). 
There is capacity for further understanding the prevalence of, and characteristics associated with, personal and 
witnessed overdose among PWID in countries reported on in the peer-reviewed and grey literature. Contextualizing 
overdose events from a nuanced geographical perspective is critical for understanding availability and coverage of 
interventions, such as opioid agonist treatment (OAT), naloxone administration training programs, and supervised 
injection facilities, to reduce overdose risk. 
Thus, the specific objectives of the current review were to: 
1. Estimate the prevalence of recent and lifetime non-fatal overdose among PWID by country, 
2. Estimate the regional and global prevalence of non-fatal overdose among PWID, 
3. Estimate the association between study level factors and non-fatal overdose prevalence, 
4. Explore the relationship between non-fatal overdose among PWID and fatal overdose among all people 
who use drugs, and 






 Data were drawn from our global systematic review on prevalence of injecting drug use (IDU) and 
sociodemographic and risk profiles of people who recently injected drugs (i.e. those who had injected within the 
previous year; see Degenhardt et al. (2017) for full details of methods). The protocols for the previous review were 
registered on PROSPERO (record numbers CRD42016052858 and CRD42016052853), and the methods were in 
accordance with PRISMA guidelines (Appendix 1). Briefly, we systematically searched peer-reviewed databases 
(Medline, Embase, and PsycINFO), internet, and grey literature, and disseminated data requests to international 
experts and agencies for data made available from January 2008. The peer-review literature search was updated 
twice, first in June of 2017 and then July 2018. We searched for data on IDU prevalence and characteristics of 
PWID including gender, age, blood borne viruses and sociodemographic risk characteristics, self-reported 
experience of overdose, self-reported witness of overdose and definitions of overdose. We did not limit our search 
by drug type (e.g. opioid overdose only) with the intention of looking at all definitions and comparing them. Search 
terms included keywords with explosions for IDU and epidemiology (Appendix 2 and 3). 
For the broader review, studies were included if they presented data on any target characteristics among PWID and 
were not limited by language. Studies with fewer than 40 participants or samples which represented a subpopulation 
(e.g. HIV-positive samples or prison populations) were excluded. References were screened by three researchers; 
full text review was conducted by two researchers, and data from eligible studies were extracted into a database and 
then double checked. In this review, studies were included if data were presented on the prevalence of self-reported 
non-fatal overdose among PWID (further details in Appendix 4). Studies were graded by literature type and 
methodological quality which is outlined in Appendix 5. 
Recent non-fatal overdose prevalence was the primary outcome variable and was defined as experiencing an 
overdose within the previous year (i.e. past 6 or 12 months). Lifetime non-fatal overdose was the secondary outcome 
variable. There were 11 continuous study-level variables recorded: year of data collection (only baseline data were 
extracted from longitudinal studies), proportion of female participants, proportion of young participants (24 years or 
younger), average age, duration of injecting (median and mean years of injecting were extracted as reported in the 




data if available), proportion of engagement in risky injecting behavior (i.e. past month receptive needle or syringe 
sharing), proportion injecting frequently (i.e. injecting drugs daily or more), proportion recently incarcerated (within 
the previous 12 months), proportion recently (within the last 12 months) or currently homeless or with unstable 
housing, proportion engaging in risky sexual behavior (i.e. engaged in sex without a condom within the previous 
year), and proportion of the sample who are currently engaged in OAT. Global region was the only country-level 
variable recorded. 
To explore the relationship between non-fatal overdose prevalence among PWID and fatal overdose prevalence, we 
extracted data from the Global Burden of Disease (GBD) study that estimates the rate of deaths per 100,000 people 
that are due to drug use disorders (Global Burden of Disease Collaborative Network, 2018). The estimates represent 
fatal overdose rates among all ages in 2017. 
Population size estimates of PWID who have experienced non-fatal overdose 
Our data analysis approach to create country-, region-, and global-level estimates was informed by methods used in 
earlier reviews (Degenhardt et al., 2017). Eligible data on the prevalence of non-fatal overdose were selected and, 
where multiple estimates were available, pooled for each country. Data was pooled separately by timeframe: recent 
and lifetime. We made initial calculations of country-level pooled proportions in accordance with agreed decision 
rules around the selection of estimates, approaches to pooling estimates within-country, and determination of 
uncertainty intervals (UIs) around estimates. Prevalence estimates of non-fatal overdose were pooled via random-
effects models. To estimate the number of PWID who had recently or ever experienced non-fatal overdose in each 
country we used previously reported country-level IDU prevalence estimates (Degenhardt et al., 2017). We 
multiplied the country-level IDU prevalence by the proportion of recent and lifetime non-fatal overdose (separately) 
among PWID and then multiplying by the country’s adult (aged 15-64 years) population size. The 95% UIs were 
simulated using the Monte Carlo method taking 100,000 draws and, because we were estimating using proportions, 
we used the binomial distribution. We derived sample size estimates based on the 95% CIs and standard errors (SE) 
of the proportion estimates in each country. Further details are presented in Appendix 6. 
Regional groupings were based on those used by the United Nations Programme on HIV/AIDS (UNAIDS), World 
Health Organization (WHO), and United Nations Office on Drug and Crime (UNODC). We calculated region-




95% CIs for each country within the regions. Where non-fatal overdose estimates were unavailable for more than 
one country in a region, we imputed the global (compared to regional) non-fatal overdose estimate for countries with 
evidence of IDU to generate that region’s estimate. The exception was when a region had only two countries (i.e. 
Australasia and North America) and a non-fatal overdose estimate was available for the country that had more than 
50% of the PWID population for that region. This approach was developed and used in previous global reviews 
(Degenhardt et al., 2017; Mathers et al., 2008). We then derived a weighted estimate and CIs, considering country 
population size. We used UN Population Division estimates of country population size in 2015 (age 15-64 years). 
We then used regional estimates to estimate the global prevalence.  
Ecological analysis of variables associated with non-fatal overdose prevalence in PWID 
To explore the associations between variations in the prevalence of recent and lifetime non-fatal overdose by study-
level characteristics of the PWID samples, we used meta-regression analyses in STATA 15. The random effects 
meta-regression analyses were conducted with recent non-fatal overdose prevalence as the outcome variable, 
considering the within-study standard errors. We did not build models for variables that were available for 25% or 
fewer studies with non-fatal overdose prevalence estimates in the database, therefore current engagement in OAT 
was excluded as a predictor variable (n=17).  
Results 
The search resulted in a total of 55,692 studies, from which 75 unique studies had data on non-fatal overdose among 
PWID and were included in this paper. This included 40 studies with recent non-fatal overdose data, and 46 studies 
with lifetime non-fatal overdose data (Table 1). Appendix 7 presents the inclusion flowchart. The median years of 
data collection were 2013 and 2011 for recent and lifetime non-fatal overdose data, respectively. Only 10% of the 
estimates were nationally-representative, and only 15% had A-grade methodological quality (Appendix 8). 
     < Table 1 here > 
Of the 75 studies included in the dataset, only 16 (21.3%) provided a definition of non-fatal overdose in the text, of 
which 13 (17.3%) characterized heroin or opioid overdose (e.g. loss of consciousness, turning blue, collapsing etc.). 
The other three (4.0%) studies that provided definitions included drug non-specific characteristics such as “heart 
stopping” and “thought of yourself as at risk of injury”. Among the 59 (78.7%) studies that did not provide 




samples who use heroin or opioids, and 45 (60.0%) gave no indication of the type of drug overdose the study might 
be referencing. There were no studies that asked about stimulant, or other non-opioid drug class, overdose. 
Out of 179 countries with evidence of IDU, data on prevalence of recent and lifetime non-fatal overdose among 
PWID were available for 26 and 29 countries, respectively (Table 2). Globally, we estimated that 20.5% (95% CI: 
15.0-26.1%) of PWID had experienced a recent non-fatal overdose, equating to an estimated 3.2 (95% UI: 1.8-5.2) 
million people. It was also estimated that 41.5% (95% CI: 34.6-48.4%) of PWID have experienced a non-fatal 
overdose in their lifetime, equating to 6.4 (95% UI: 3.6-9.9) million people (see Table 2).  
< Table 2 here > 
Studies suggested that PWID in Australasia (11.9% [95% CI: 7.9-16.2%]) and Western Europe (15.6% [95% CI: 
14.1-17.2%]) experienced the lowest rates of recent non-fatal overdose. Estimates were highest in Central Asia 
(25.4% [95% CI: 21.6-29.5%], and East and Southeast Asia (23.5% [95% CI: 19.5-27.9%]). East and Southeast 
Asia, North America, and Eastern Europe made up nearly two thirds of the estimated number of PWID who had 
recently overdosed (0.9 [95% UI: 0.7-1.2], 0.5 [95% UI: 0.2-0.9], and 0.5 [95% UI: 0.2-1.0] million people 
respectively). We found that the lowest point estimates for recent non-fatal overdose were Thailand (2.9% [95% CI: 
1.3-5.7%]) and Moldova (4.8% [95% CI: 3.5-6.1%]) (see Appendix 9 for national estimates). The Central Asian 
countries all had estimates above the global estimate (Kyrgyzstan, 23.7% [95% CI: 20.1-27.6%]; Kazakhstan, 24.1% 
[95% CI: 20.4-28.0%]; Tajikistan, 34.1% [95% CI: 29.6-38.8%]), and Viet Nam had the highest estimate for recent 
non-fatal overdose among PWID (36.1%, 95% CI: 30.7-41.9%). 
< Figure 1 here > 
< Figure 2 here > 
Lifetime experience of non-fatal overdose was lowest in East and Southeast Asia (34.4% [95% CI: 29.6-39.4%]) and 
Western Europe (40.7% [95% CI: 33.3-48.4]). Estimates were highest in Australasia (Australia; 51.4% [95% CI: 
40.1-62.7%]), Central Asia (50.3% [95% CI: 46.4-54.2%]) and Sub-Saharan Africa (49.8% [95% CI: 42.6-57.0%]). 
Again, East and Southeast Asia, Eastern Europe and North America accounted for the largest number of recent 
PWID who have ever experienced a non-fatal overdose (1.4 [95% UI: 1.0-1.8], 1.3 [95% UI: 0.6-2.1], and 1.1 [95% 




The results of the meta-regressions on recent non-fatal overdose are presented in Table 3, and study-level data 
characteristics and definitions of overdose are presented in Appendix 8. We found that studies with higher 
percentages of PWID with frequent injecting (meta-regression coefficient = 0.18, 95% CI: 0.09-0.26, p<0.001), 
homeless/unstable housing (β = 0.30, 95%CI: 0.14-0.46, p=0.001), and younger (β = 0.18, 95%CI: 0.01-0.36, 
p=0.04) samples were positively associated with the prevalence of non-fatal overdose. Duration of injecting (β = -
0.01, 95%CI: -0.01-0.00, p=0.039) and year of data collection (β = -0.01, 95%CI: -0.02-0.00, p=0.010) were 
associated with lower prevalence of recent non-fatal overdose. Compared to Eastern Europe, Asian (β = 0.14, 
95%CI: 0.05-0.22 p<0.002) and North American (β = 0.11, 95%CI: 0.05-0.17, p=0.001) studies had higher 
prevalence estimates of recent non-fatal overdose. Age, gender, injecting and sexual risk behaviours, and recent 
incarceration of the sample were not associated with recent non-fatal overdose. Prevalence of lifetime non-fatal 
overdose was associated with frequent injecting (β = 0.19, 95%CI: 0.05-0.33 p=0.010); samples with higher 
prevalence of frequent injecting had a higher prevalence of PWID reporting lifetime non-fatal overdose (Appendix 
10). All other variables were not significantly associated with lifetime non-fatal overdose prevalence. 
< Table 3 > 
To illustrate the relationship between non-fatal overdose and fatal overdose, we plotted our available country-level 
prevalence estimates against drug use disorder death rate (per 100,000 people) data sourced from the GBD study 
(Figures 3 and 4). The graphs suggest a weak, but positive relationship between non-fatal overdose and drug use 
disorder deaths.  
< Figure 3 here > 
< Figure 4 here > 
There were 11 studies that asked PWID whether they had witnessed an overdose. Results were varied: the 
proportion of PWID who reported witnessing an overdose in their lifetime (five estimates, from Spain, Viet Nam 
and the USA) ranged from 45.0% to 76.3%. The proportion of PWID who had recently (previous six or 12 months) 
witnessed an overdose ranged from 22.1% to 84.0%, however, outside of Australia all estimates were above 45% 
(Appendix 11). Due to a small number of estimates for each time frame we did not pool the available estimates of 





This review builds on a body of work investigating the epidemiology of IDU and is the first quantification of non-
fatal overdose prevalence among PWID. Using studies from 41 countries we estimated that around one in five 
PWID, or 3.2 million people, have experienced an overdose in the previous year, and that one in three PWID have 
ever experienced an overdose. There is large variation in non-fatal overdose rates between and within major global 
regions. Notably, studies from North American and Asian countries recorded higher rates of non-fatal overdose 
compared to other regions. Higher levels of recent non-fatal overdose were associated with younger participants, 
higher levels of daily or more injecting, and higher levels of homelessness among samples. We undertook some 
exploratory analyses to see whether the published non-fatal overdose estimates were associated with the modelled 
drug-related fatalities reported in the GBD study and found that the trend of the former mapped onto the latter. 
The prevalence estimates presented are consistent with findings from a previous systematic review investigating 
fatal and non-fatal overdose among people who use drugs (Martins et al., 2015). They found that among samples of 
PWID, recent non-fatal overdose ranged from 6.7% to 32.7% (compared to 20.5%, 95%CI 15.0-26.1%) and lifetime 
non-fatal overdose ranged from 29.0% to 59.0% (compared to 41.5%, 95%CI: 34.6-48.4%). Unlike the present 
review, they only included studies from the UK, the USA, Russia and Canada and most of the included data were 
collected before 2005.  
Our findings also highlight that overdose is associated with elevated exposure to other risks and harms (Fairbairn et 
al., 2008; T. Kerr et al., 2007). Interestingly, younger and more inexperienced samples of PWID had higher 
prevalence of non-fatal overdose, however there is evidence to suggest that older PWID with longer injecting 
careers are at a higher risk of fatally overdosing (Brady, Giglio, Keyes, DiMaggio, & Li, 2017; Darke, Ross, Zador, 
& Sunjic, 2000; Darke & Zador, 1996).  
Our findings may be used to investigate the extent to which PWID are at risk of morbidity and mortality associated 
with non-fatal overdose. An Australian study found that more than 80% of PWID who had overdosed on heroin had 
experienced at least one sequelae, a large proportion of those due to physical injuries sustained when falling while 
comatose (Warner-Smith et al., 2002). With respect to mortality, the ratio of non-fatal to fatal heroin overdose has 
been measured at 31.3:1 (Darke, Mattick, & Degenhardt, 2003). If we consider these results in conjunction with 




100,000 are dying from overdose each year. Although coarse, we can compare this to the Global Burden of Disease 
study that estimated over 160,000 people died from overdose and other drug-related deaths in 2017 (Gakidou et al., 
2017). Thus, PWID may be making up a sizable proportion of people who die from overdose every year. 
The financial burden of overdose on the community is significant. For example, studies analysing emergency 
department data consistently show that presentations of opioid overdose are increasing in the USA (Calcaterra, 
Glanz, & Binswanger, 2013; Hasegawa, Espinola, Brown, & Camargo, 2014; Jones & McAninch, 2015; Martins et 
al., 2015). These presentations equate to nearly $100 million USD for heroin overdose, and over $600 million USD 
for opioid overdose every year (Hsu, McCarthy, Stevens, & Mukamal, 2017). In Australia, it was estimated that 
annual ambulance call outs for overdose cost around $1 million AUD in 1997-98 (Dietze, Cvetkovski, Rumbold, & 
Miller, 2000). 
Intervention efforts have been implemented to reduce the financial burden of overdose. Studies from Europe, the 
USA and Russia have conducted cost-benefit analysis on naloxone training distribution to increase treatment of 
overdose and prevent fatalities (Coffin & Sullivan, 2013a, 2013b; Langham, Wright, Kenworthy, Grieve, & Dunlop, 
2018). It was repeatedly found that distributing naloxone to adults at risk of witnessing an overdose (i.e. PWID or 
friends and family of PWID) with training was highly cost effective across settings (Coffin & Sullivan, 2013a, 
2013b; Langham et al., 2018). We found that around half, and up to 84%, of PWID reported recently witnessing an 
overdose. These data reflect participants who have witnessed at least one overdose and likely underestimates the 
capacity there is to prevent fatalities by training and equipping PWID with overdose prevention strategies. Naloxone 
administration training programs are also considered useful and effective by PWID, one study found that there was a 
43% increase in PWID self-perceived ability to inject naloxone into someone who was overdosing (Chronister et al., 
2018). 
Other intervention efforts that reduce the risk of overdose and the morbidity associated with non-fatal overdose 
include OAT programs, and supervised injection facilities. OAT is a necessary intervention to reduce the risk of 
overdose (Davoli et al., 2007; Schwartz et al., 2013; Sordo et al., 2017); however, many countries are yet to 
introduce OAT or have only very low levels of coverage (Larney et al., 2017). There was not enough statistical 
power to investigate the relationship between study-level OAT engagement and non-fatal overdose, however future 




been implemented in 10 countries, including Australia, Canada and in Europe (International Network of Drug 
Consumption Rooms, 2015). These facilities aim to assist in reversing overdose events in real time (Wood, Kerr, 
Montaner, et al., 2004). They have also been successful in acting as low-threshold targets for drug treatment services 
(Kimber et al., 2008), and decreasing public injecting, public overdosing, and ambulance callouts for overdose (T. 
Kerr, Tyndall, Li, Montaner, & Wood, 2005; Madah-Amiri et al., 2018; Salmon, Van Beek, Amin, Kaldor, & 
Maher, 2010; Wood, Kerr, Small, et al., 2004).  
Finally, stimulant overdose is relatively unexplored compared to opioids. Most studies (60%) did not include 
definitions of “overdose”, and we found that 36% of studies either defined heroin or opioid-specific overdose 
characteristics, asked about heroin- or opioid-overdose, or asked samples specifically using heroin or opioids. It is 
likely, however, that many PWID have either experienced or witnessed a stimulant overdose. Unfortunately, there 
were no included data sources that specified overdose due to non-opioid drug types, therefore we could not compare 
the difference in prevalence across overdose types. Future research investigating overdose by different drug classes 
as well as drug combinations remains important for informing harm reduction, medical and emergency services. 
Knowledge about the characteristics of a stimulant overdose need to be communicated to this community, as has 
been done with recognising an opioid overdose, so that interventions may be developed and implemented as we 
progress to reduce overdose fatalities. 
Our review was subject to several limitations. Firstly, non-fatal overdose is biologically complex and there is no 
clear universal definition that encompasses all drug classes. We found that most studies implicitly refer to opioid 
overdose when surveying PWID, however, we know that stimulant injecting makes up a substantial proportion of 
IDU in many countries including Czechia, Denmark, Serbia, Slovenia, Thailand, Puerto Rico, and Nigeria 
(Degenhardt et al., 2017). Knowledge of opioid overdose symptoms is generally good among people who use drugs 
(Chronister et al., 2016; Mcgregor, Darke, Ali, & Christie, 1998; Nielsen et al., 2018), however, it remains unclear 
whether they can equally identify the characteristics of a stimulant overdose. Further, a clear definition is necessary 
for investigators so as not to underestimate the prevalence of stimulant or polydrug overdose. Future studies are 
needed to provide universal definitions for non-fatal overdose for different and combined drug classes, and when 




Secondly, the estimates were limited by the data available. Some countries had robust, recent estimates from 
multiple studies with substantial geographical variation, such as those in Australasia, North America and Europe. 
Other regions lacked data and were driven by one or two countries with less sub-national geographical variation, 
such as Latin America, East and Southeast Asia and Central Asia. Countries in Sub-Saharan Africa, the Middle East 
and North Africa, the Caribbean, and the Pacific Islands had very little or no data at all. These regions include 
countries with the highest population size estimates of non-fatal overdose. These high rates may be driven by the 
riskier nature of IDU in that country (or by the sub-region within a country), in so much that injecting is more 
prevalent in that country and therefore has been targeted for this type of research. Therefore, we may have 
overestimated the pooled regional prevalence of non-fatal overdose if studies were only conducted in a small 
number of high-risk locations within the region. It may also be likely, however, that neighbouring countries are 
experiencing similar rates of overdose but there are few resources to investigate the prevalence of this issue. For 
example, in South Asia, Iran has the highest prevalence rate of recent non-fatal overdose and is the only country in 
that region with an estimate. In other countries within South Asia where we know the size of the PWID population, 
but do not know the prevalence rate of recent non-fatal overdose, the prevalence rates were imputed based on the 
global prevalence rate for the purpose of deriving the pooled regional estimate. However, if the other countries in 
south Asia are experiencing non-fatal overdose in similar proportions to Iran, then we have grossly underestimated 
the regional prevalence.  
Our review was limited to looking at country-level data, when we know that there can be substantial variation within 
a country. For example, in the USA, there were eligible studies with estimates of recent non-fatal overdose ranging 
from 9% in San Francisco to over 50% in Boston (Leon, Cardoso, Mackin, Bock, & Gaeta, 2018; Robinson et al., 
2017). Similarly, pooling studies in Viet Nam reporting on lifetime non-fatal overdose resulted in a lower estimate 
than recent non-fatal overdose in our results. This is an artefact of using different studies to generate estimates for 
these two different outcomes that are temporally nested. Also, to have as complete data as possible we included all 
studies that were published since 2008, which included data that were collected from 2002 onward. The risk of non-
fatal overdose varies over time according to many factors, including drug market characteristics and the introduction 
of harm reduction interventions (such as naloxone administration training and prescriptions), which was not 
captured in this review. The recent overdose epidemic has been well documented in the United States and Canada, 




United Nations Office on Drugs and Crime (UNODC), 2018). It may be likely, therefore, that our results are not 
representative of the current climate and are in fact an underestimate due to the rises in overdose that have occurred 
more recently. 
The meta-regression analyses resulted in several inconsistencies with what we know about overdose. For example, 
recent incarceration was not associated with non-fatal overdose prevalence, but younger age and shorter injecting 
careers were associated with overdose. This is surprising given that older age, longer injecting careers and recent 
prison release are frequently reported as risk factors for fatally overdosing (Binswanger et al., 2007; Brady et al., 
2017). One explanation might be that our findings represent a survival bias; in so much that survivors of overdose 
events are more likely to enter into and be captured in a study. This complicates identifying those individuals at 
elevated risk and in need of targeted harm reduction through this methodology. 
Finally, our results may be an under-estimate due to our exclusive inclusion of self-report data. Ambulance or 
hospital presentation data may assist with making our estimates more reliable. However, due to the illicit nature of 
IDU, many PWID are concerned about calling emergency services when they are with someone who has overdosed 
(Chronister et al., 2016) which may mean that a limited number of non-fatal overdose presentations get recorded 
through these systems. If we are to rely on self-report data to inform intervention practice, it is necessary to 
construct and use an appropriate definition for non-fatal overdose. Employing a global definition will aid 
epidemiology research that aims to compare different countries and regions, and in doing so advise intervention 
policies accordingly. 
This study is the first quantification of the global prevalence of non-fatal overdose among PWID, finding that 
globally over one in three have suffered a non-fatal overdose, equivalent to approximately 3.2 million people. The 
results in this study have potential utility for estimating service implementation of programs such as OAT, naloxone 
administration training, and supervised injection facilities.  
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Figure 3: Estimates of recent non-fatal overdose (OD) and drug use disorder death rates reported by the 







Figure 4: Estimates of lifetime non-fatal overdose (OD) and drug use disorder death rates reported by the 







Table 1: Recent and lifetime non-fatal overdose estimates among people who inject drugs 1 







Australia 2002 12 months 3715 11.89 (Kimber et al., 2008; Salmon, Van 
Beek, Amin, Grulich, & Maher, 2009) 
Australia 2006 12 months 246 5.69 (Conroy, Kimber, Dolan, & Day, 2008) 
Australia 2014 12 months 99 18.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 761 16.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 70 3.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 490 13.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 228 11.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 69 6.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 436 19.00 (The Kirby Institute, 2015) 
Australia 2014 12 months 225 22.00 (The Kirby Institute, 2015) 
Australia 2015 12 months 888 8.20 (Stafford & Breen, 2016) 
Australia 2007 Lifetime 9778 35.00 (Salmon et al., 2009) 
Australia 2002 Lifetime 615 54.31 (Darke, Mills, Ross, & Teesson, 2011) 
Australia 2007 Lifetime 99 61.00 (D. Kerr, Dietze, Kelly, & Jolley, 2008) 
Australia 2015 Lifetime 888 41.00 (Stafford & Breen, 2016) 
Belgium 2009 12 months 219 17.00 (Reitox National Focal Point, 
Lamkaddem, & Roelands, 2011) 
Belgium 2010 12 months 251 15.00 (Reitox National Focal Point et al., 
2012) 
Belgium 2012 12 months 227 14.50 (Reitox National Focal Point, 
Plettinckx, Antoine, Blanckaert, & van 
Bussel, 2014) 
Bosnia and Herzegovina 2012 12 months 199 8.54 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 12 months 209 11.96 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 12 months 200 12.00 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 12 months 128 3.13 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 12 months 257 8.17 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 Lifetime 199 45.73 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 Lifetime 209 35.89 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 Lifetime 200 27.00 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 Lifetime 128 21.88 (Bacak & Dominkovic, 2012) 
Bosnia and Herzegovina 2012 Lifetime 257 49.81 (Bacak & Dominkovic, 2012) 
Canada 2005 12 months 321 19.00 (Cox et al., 2008) 
Canada 2013 12 months 272 29.04 (Shaw et al., 2015) 
Canada 2011 Lifetime 115 59.00 (Leclerc, Gutierrez, Morissette, 
Larouche, & Gagnon, 2012) 
Canada 2016 Lifetime 197 24.70 (Mitra et al., 2017) 
Colombia 2011 Lifetime 237 38.30 (Berbesi Fernández, Montoya Vélez, 
Segura Cardona, & Mateu-Gelabert, 
2011) 
Colombia 2011 Lifetime 297 25.40 (Berbesi Fernández et al., 2011) 
Croatia 2015 Lifetime 397 44.10 (Handanagic et al., 2016) 
Croatia 2015 Lifetime 255 40.70 (Handanagic et al., 2016) 
Croatia 2015 Lifetime 174 33.40 (Handanagic et al., 2016) 
Estonia 2013 12 months 328 27.00 (Reitox National Focal Point, 2015) 
Estonia 2005 Lifetime 331 65.86 (Talu et al., 2010) 
Estonia 2007 Lifetime 350 54.86 (Uuskula et al., 2010) 
Estonia 2013 Lifetime 328 68.00 (Reitox National Focal Point, 2015) 
Georgia 2009 12 months 307 23.30 (Curatio International Foundation & 
Public Union Bemoni, 2009) 
Georgia 2009 12 months 206 29.50 (Curatio International Foundation & 
Public Union Bemoni, 2009) 
Georgia 2009 12 months 204 16.00 (Curatio International Foundation & 
Public Union Bemoni, 2009) 
Georgia 2009 12 months 205 10.40 (Curatio International Foundation & 











Georgia 2009 12 months 205 15.30 (Curatio International Foundation & 
Public Union Bemoni, 2009) 
Georgia 2015 12 months 357 6.30 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Georgia 2015 12 months 290 8.50 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Georgia 2015 12 months 289 6.60 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Georgia 2015 12 months 288 9.70 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Georgia 2015 12 months 277 8.10 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Georgia 2015 12 months 289 11.80 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Georgia 2015 12 months 247 5.60 (Curatio International Foundation & 
Public Union Bemoni, 2015) 
Germany 2014 12 months 2077 14.00 (Wenz et al., 2016) 
Germany 2014 Lifetime 2077 55.00 (Wenz et al., 2016) 
Greece 2008 Lifetime 287 50.17 (Zavitsanou et al., 2010) 
India 2013 Lifetime 891 40.85 (Ambekar, Rao, Mishra, & Agrawal, 
2015) 
Indonesia 2015 Lifetime 171 34.70 (Persaudaraan Korban Napza Indonesia 
(PKNI), 2014) 
Iran 2007 12 months 1416 33.47 (Assari et al., 2014) 
Iran 2007 Lifetime 887 44.40 (Amin-Esmaeili, Rahimi-Movaghar, 
Razaghi, Baghestani, & Jafari, 2012) 
Iran 2007 Lifetime 1416 56.41 (Assari et al., 2014) 
Israel 2010 Lifetime 199 47.00 (WHO, 2010) 
Kazakhstan 2010 12 months 503 24.10 (Population Services International, 
2010) 
Kazakhstan 2013 Lifetime 600 48.18 (Rosenkranz et al., 2016) 
Kenya 2012 Lifetime 150 48.00 (Syvertsen, 2014) 
Kyrgyzstan 2010 12 months 520 23.70 (Population Services International, 
2010) 
Kyrgyzstan 2013 Lifetime 900 58.80 (Rosenkranz et al., 2016) 
Latvia 2007 Lifetime 401 44.00 (Expanding Network for 
Comprehensive and Coordinated Action 
on HIV/AIDS prevention among IDUs 
and Bridging Population (ENCAP), 
2009) 
Libya 2010 Lifetime 328 40.90 (Mirzoyan et al., 2013) 
Lithuania 2008 Lifetime 400 48.00 (Expanding Network for 
Comprehensive and Coordinated Action 
on HIV/AIDS prevention among IDUs 
and Bridging Population (ENCAP), 
2009) 
Malaysia 2010 6 months 460 20.00 (Bazazi et al., 2015) 
Malaysia 2010 Lifetime 460 43.30 (Bazazi et al., 2015) 
Mauritius 2009 Lifetime 511 25.40 (Johnston, Saumtally, Corceal, 
Mahadoo, & Oodally, 2011) 
Mauritius 2011 Lifetime 499 82.36 (Mauritius: Ministry of Health and 
Quality of Life, 2011) 
Mexico 2012 6 months 735 10.10 (Meacham, 2017) 
Mexico 2012 Lifetime 735 54.60 (Meacham, 2017) 
Moldova 2013 12 months 365 5.70 (Global Fund, 2013) 
Moldova 2013 Lifetime 365 40.50 (Global Fund, 2013) 
Moldova 2013 12 months 297 3.60 (Global Fund, 2013) 











Moldova 2013 12 months 363 5.30 (Global Fund, 2013) 
Moldova 2013 Lifetime 363 34.10 (Global Fund, 2013) 
Moldova 2013 12 months 115 0.00 (Global Fund, 2013) 
Moldova 2013 Lifetime 115 40.50 (Global Fund, 2013) 
Nepal 2013 Lifetime 300 33.33 (Ojha, Sigdel, Verthien, & Khadga, 
2014) 
New Zealand 2014 6 months 102 12.00 (Wilkins, Prasad, Wong, & Rychert, 
2015) 
Norway 2011 Month 1760 8.13 (Gjersing & Bretteville-Jensen, 2013) 
Norway 2013 12 months 1355 30.80 (Bretteville-Jensen, Lillehagen, 
Gjersing, & Andreas, 2015) 
Puerto Rico 2007 12 months 124 29.30 (Zerden, Marilis Lopez, & Lundgren, 
2010) 
Russian Federation 2010 12 months 285 7.02 (Cepeda, Niccolai, Eritsyan, Heimer, & 
Levina, 2013) 
Russian Federation 2010 12 months 299 32.78 (Cepeda et al., 2013) 
Russian Federation 2014 12 months 811 16.28 (Heimer, Lyubimova, Barbour, & 
Levina, 2016) 
Slovenia 2008 12 months 107 40.19 (Reitox National Focal Point, 2010) 
Spain 2009 Lifetime 726 54.41 (Sarasa-Renedo et al., 2014) 
Sweden 2007 Lifetime 81 58.00 (Hakansson, Isendahl, Wallin, & 
Berglund, 2011) 
Sweden 2009 Lifetime 68 48.53 (Hakansson, Isendahl, Wallin, & 
Berglund, 2012) 
Taiwan 2013 Lifetime 827 28.90 (Yen et al., 2014) 
Tajikistan 2010 12 months 431 34.10 (Population Services International, 
2010) 
Thailand 2009 6 months 273 2.93 (Fairbairn et al., 2012) 
Thailand 2008 Lifetime 252 29.76 (T. Kerr et al., 2010) 
Thailand 2009 Lifetime 738 24.00 (Prybylski et al., 2015) 
Thailand 2009 Lifetime 309 17.50 (Prybylski et al., 2015) 
Thailand 2010 Lifetime 202 13.37 (Visavakum et al., 2016) 
Thailand 2011 Lifetime 438 27.17 (Fairbairn et al., 2015) 
Ukraine 2013 12 months 5304 6.90 (Makarenko et al., 2017) 
Ukraine 2015 12 months 9405 6.00 (Barska & Sazonov, 2016) 
United Kingdom (exc. 
Scotland) 
2014 12 months 3850 15.35 (O'Halloran et al., 2017) 
United Kingdom 
(England) 
2011 Lifetime 156 39.10 (Marufu, Williams, Hill, Tibble, & 
Verma, 2012) 
United States  2006 12 months 348 43.10 (Zerden et al., 2010) 
United States  2010 6 months 283 2.80 (Stephens, 2017) 
United States  2009 12 months 51 31.37 (Bazazi, Yokell, Fu, Rich, & Zaller, 
2011) 
United States  2009 12 months 443 16.25 (Jenkins et al., 2011) 
United States  2017 12 months 1943 19.40 (Glick et al., 2018) 
United States  2012 12 months 512 18.80 (Robinson et al., 2017) 
United States  2012 12 months 557 9.30 (Robinson et al., 2017) 
United States  2012 12 months 639 15.70 (Robinson et al., 2017) 
United States  2014 6 months 576 7.90 (Meacham, 2017) 
United States  2015 12 months 486 21.80 (Tsui, Burt, Thiede, & Glick, 2018) 
United States  2015 12 months 592 21.79 (Al-Tayyib, Koester, Langegger, & 
Raville, 2017) 
United States  2016 Month 222 52.70 (Leon et al., 2018) 
United States  2016 12 months 283 33.00 (Hunter et al., 2018) 
United States  2012 Lifetime 462 31.00 (Grau, Zhan, & Heimer, 2016) 
United States  2010 Lifetime 283 36.80 (Stephens, 2017) 
United States  2010 Lifetime 91 54.95 (Bonar & Rosenberg, 2011) 











United States  2014 Lifetime 576 41.50 (Meacham, 2017) 
United States  2016 Lifetime 222 75.68 (Leon et al., 2018) 
United States 2008 Lifetime 195 31.28 (Havens et al., 2011) 
Viet Nam 2003 12 months 299 36.12 (Bergenstrom et al., 2008) 
Viet Nam 2003 Lifetime 299 43.48 (Bergenstrom et al., 2008) 





Table 2: Prevalence of recent and lifetime experience of non-fatal overdose (OD) among people who inject drugs (PWID) by region and globally 3 
 Recent non-fatal OD Lifetime non-fatal OD 




PWID (95% CI) 
Number of PWID who 
experienced recent non-fatal 






PWID (95% CI) 
Number of PWID who have ever 
experienced non-fatal OD (95% 
CI) 
Eastern Europe 6/17 16.6 (7-26.2) 500,500 (161,500-986,500) 5/17 41.5 (33.8-49.1) 1,252,500 (591,000-2,062,000) 
Western Europe 7/33 15.6 (14.1-17.2) 157,500 (106,500-219,000) 5/33 40.7 (33.3-48.4) 410,500 (255,500-600,500) 
East and southeast Asia 3/17 23.5 (19.5-27.9) 936,500 (678,500-1,234,500) 5/17 34.4 (29.6-39.4) 1,372,000 (1,013,500-1,777,000) 
South Asia 1/9 22 (16.6-27.6) 225,500 (180,000-376,000) 3/9 44.6 (41.7-47.6) 456,500 (347,500-575,500) 
Central Asia 3/5 25.4 (21.6-29.5) 71,500 (43,000-105,000) 2/5 50.3 (46.4-54.2) 141,500 (86,500-204,000) 
Caribbean 1/15 23.2 (16.5-30.2) 18,500 (10,500-29,000) 0/15 NK NK 
Latin America 1/20 19.1 (13.5-24.9) 349,000 (229,000-518,000) 2/20 42.4 (38.6-46.1) 772,500 (560,000-1,008,000) 
North America 2/2 23 (18.7-27.3) 545,000 (232,500-931,000) 2/2 44.5 (31.5-57.6) 1,055,500 (432,000-1,879,500) 
Pacific Island states & 
terr. 
0/17 NK NK 0/17 NK NK 
Australasia 2/2 11.9 (7.9-16.2) 13,500 (8,000-20,500) 1/2 51.4 (40.1-62.7) 59,500 (39,500-82,000) 
Sub-Saharan Africa 0/47 NK NK 2/47 49.8 (42.6-57.0) 685,500 (195,500-1,383,000) 
Middle East & North 
Africa 
0/22 NK NK 2/22 46.2 (39.6-53.0) 161,500 (85,500-251,500) 
Global 26/206 20.5 (15-26.1) 3,167,500 (1,765,500-5,161,000) 29/206 41.5 (34.6-48.4) 6,411,000 (3,631,500-9,887,500) 
NK: not known; a Among total number of countries in that region, including those without evidence of injecting 4 
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Table 3: Correlates of recent non-fatal overdose  7 
Models on recent non-fatal overdose prevalence 




βa SEb 95% CIs pc Adjusted R2 
Study-level exposure variables 
Percentage of sample female 66 22.9% 0.01 0.10 (-0.19, 0.22) 0.918 -1.66% 
Median/mean age of sampled 62 37 0.00 0.00 (-0.01, 0.01) 0.749 -1.61% 
Duration of injectingd 46 16 -0.01 0.00 (-0.01, -0.00) 0.039 7.97% 
Percentage of sample engaging in injecting risk behaviour 33 14.0% 0.07 0.10 (-0.14, 0.28) 0.487 -1.56% 
Year of data collection 70 2013 -0.01 0.00 (-0.02, -0.00) 0.010 8.39% 
Percentage of sample injecting daily or more 49 43.0% 0.18 0.04 (0.09, 0.26) <.001 25.95% 
Percentage of sample with recent incarceration 20 11.4% 0.12 0.10 (-0.08, 0.32) 0.220 3.86% 
Percentage of sample who were recently homeless 23 31.4% 0.30 0.08 (0.14, 0.46) 0.001 40.03% 
Percentage of sample who are young 41 11.7% 0.18 0.09 (0.01, 0.36) 0.040 8.11% 
Percentage of sample who are engaging in risky sexual 
behaviour 
35 13.8% 0.09 0.07 (-0.05, 0.23) 0.198 1.81% 
Region (vs. Eastern Europe) 70         19.84% 
     Western Europe  0.08 0.04 (0.00, 0.16) 0.054  
     North America  0.11 0.03 (0.05, 0.17) 0.001  
     Australasia  0.01 0.04 (-0.06, 0.08) 0.796  
     Asia (Central Asia, East and South east Asia, South Asia)  0.14 0.04 (0.05, 0.22) 0.002  
     South America   0.08 0.07 (-0.07, 0.22) 0.299  
a meta-regression co-efficient; b standard error; c p-value; d reported in years 8 
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